Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


22 12, 2015

Hopeful news about first PD-1 inhibitor

Tags: , , , |2 Comments

Another exciting, new immunotherapy may be on the horizon: Keytruda In meetings of well informed patient activists and experts after ASH, several in the group were excited about a new class of drug called PD-1 inhibitors. Jenny Ahlstrom was practically doing back flips over it. Here's info on the first of let's hope are several

1 12, 2015

More about elotuzumab (Empliciti). Are immunotherapies the answer?

Tags: , , , , , |0 Comments

In my haste to get the news out about elotuzumab's FDA approval yesterday, I mistakenly relied on a Cure Magazine article that stated Kyprolis was the drug used in combination with elo. I was surprised, but ran with it. I should have known better. The Cure Magazine article was mistaken. Elotuzumab (Empliciti), Revlimid and dexamethasone

27 11, 2015

T cell immunotherapy advancing rapidly

Tags: , , , |8 Comments

Tuesday night I was part of a panel that questioned myeloma T cell therapy pioneer, Dr. Ivan Borrello of Johns Hopkins in Baltimore. The hour shed light on how and why researchers are so hopeful about the potential of T cell immunotherapy. Here is the replay link to the broadcast, courtesy of Cure Talks:

16 11, 2015

BREAKING NEWS: FDA approves daratumumab

Tags: , , |0 Comments

I expected daratumumab to garner FDA approval sometime after ASH. So when I saw a news alert earlier today announcing that Darzalex had been approved, I didn't pay any attention. But it didn't take long for me to figure out that Darzalex is the new trade name for daratumumab. By any name, this is wonderful

14 10, 2015

Reader celebrating great response to daratumumab

Tags: , |10 Comments

I'm often said our readers are my best resource. Early reports about the new immunotherapy, daratumumab, have been good. Mike, from North Carolina, recently enrolled in a dara trial. He emailed me about how great it's working for him and agreed to share an email he sent his friends, trumpeting the early results. Here's a

7 10, 2015

Immunotherapy angst: Why is myeloma code so tough to crack?

Tags: , , |2 Comments

We were all so excited! Dying myeloma patient, Stacy from Minnesota, responded miraculously to Mayo Clinic's experimental measles vaccine therapy. Yet apparently attempts to match this early success is fleeting. U.S. News and World Report ran an excellent update yesterday about how researchers are mobilizing patient's immune systems to fight their cancer. The ongoing Mayo

27 08, 2015

BREAKING NEWS: Daratumumab pushes forward toward FDA approval

Tags: , , , , |1 Comment

Important news as the promising new immunotherapy, daratumumab, continues to move swiftly toward FDA approval. My friends at Genmab and Jannsen in the Netherlands emailed me details last evening, along with some helpful background information to review: Daratumumab is an investigational human anti-CD38 monoclonal antibody that received Breakthrough Therapy Designation from the FDA in May,

12 08, 2015

BREAKING NEWS: MMRF helps push expanded access for dararumumab

Tags: , , , |2 Comments

Today is your last chance to participate in a focus group study using your smart phones. Amazon gift cards will be given to all who participate. Contact Kristin Mraz,Community Recruitment Manager - WEGO Health, 177 Tremont Street, 3rd Floor,Boston, MA,02111 - cell:  518.774.6114 - office:  617.863.7745 - fax:  617.426.5027 - I've worked with these

23 06, 2015

International research produces promising new immunotherapy

Tags: , , , |13 Comments

With so much focus on me and my Iowa trip, I'm afraid I've been neglecting some important multiple myeloma news.  Before I share details about my bone marrow biopsy early this morning, I want to help you get caught up. Here's a press release I received yesterday, confirming that ImMucin--an experimental new anti-myeloma drug--has been

17 03, 2015

Sub-q daratumumab study announced

Tags: , , |0 Comments

Following Takeda's lead with sub-q Velcade, Genmab hopes that their new immunotherapy, daratumumab, will work sub-q, too.  I like it!  These guys aren't wasting any time.  Daratumumab isn't even FDA approved yet: Genmab to initiate Phase 1 trial of multiple myeloma therapy Immuno-Oncology News - Leanor Mateus Ferreira March 13, 2014 Biotech company Genmab A/S

23 02, 2015

Myeloma therapy advances big and small

Tags: , , , |12 Comments

Speaking of new treatment options, here's an excerpt from an excellent summary of what I consider to be "stopgap" myeloma therapy measures until new immunotherapy technology moves front and center: Treatment Triplets Offer New Strategies in Relapsed Multiple Myeloma Anita T. Shaffer - Published Online: Friday, February 20, 2015 The treatment options for patients

8 01, 2015

If this works out a lot of us may live longer…

Tags: , , , , , , |0 Comments

Our next, best shot: immunotherapy agents that attack CD38 proteins on the cell walls of multiple myeloma cells: Anti-CD38 antibodies poised to transform myeloma treatment By: PATRICE WENDLING, Oncology Practice Digital Network Jan 5, 2015 Vitals Key clinical point: The investigational anti-CD38 antibodies SAR650984 and daratumumab in combination with standard regimens were highly active in

14 12, 2014

A new twist using T cells to fight multiple myeloma

Tags: , , |5 Comments

Here's exciting news about a completely different type of immunotherapy: individually modified T Cells. According to Dr. June, this T-cell therapy works against multiple myeloma, too: Therapeutic Efficacy of Chimeric Antigen Receptor T Cells Carl H. June, MD Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; Translational Research Program, Abramson Family

8 12, 2014

Hopeful immunotherapy update from ASH

Tags: , , |4 Comments

As promised, here's an update on the two hottest immunotherapies at ASH this year: daratumumab and SAR650984. Here are excerpts from Silas Inman's article, Anti-CD38 Antibodies Highly Effective in Multiple Myeloma, on Sunday: Anti-CD38 monoclonal antibodies continue to demonstrate promise across a variety of settings, generating excitement that a new treatment paradigm could be on